US 12,351,632 B2
Anti-TCR antibody molecules and uses thereof
Seng-Lai Tan, Sudbury, MA (US); Brian Edward Vash, Cambridge, MA (US); Jonathan Hsu, Waltham, MA (US); Dilini Charmain Gunasekera, Cambridge, MA (US); Sangeetha Sagar Palakurthi, East Walpole, MA (US); and Andreas Loew, Boston, MA (US)
Assigned to Marengo Therapeutics, Inc., Cambridge, MA (US)
Filed by Marengo Therapeutics, Inc., Cambridge, MA (US)
Filed on Sep. 22, 2023, as Appl. No. 18/472,920.
Application 18/472,920 is a continuation of application No. 17/256,917, granted, now 11,845,797, previously published as PCT/US2019/040592, filed on Jul. 3, 2019.
Claims priority of provisional application 62/808,700, filed on Feb. 21, 2019.
Claims priority of provisional application 62/788,674, filed on Jan. 4, 2019.
Claims priority of provisional application 62/737,829, filed on Sep. 27, 2018.
Claims priority of provisional application 62/693,653, filed on Jul. 3, 2018.
Prior Publication US 2024/0076377 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/078 (2010.01)
CPC C07K 16/2809 (2013.01) [A61K 35/17 (2013.01); A61K 40/10 (2025.01); A61K 40/11 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/283 (2013.01); C07K 16/2878 (2013.01); C12N 5/0634 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 33 Claims
 
1. A method of selective expansion of a subset of T cells that express a T cell receptor (TCR) in a T cell population, the method comprising:
contacting the T cell population with a composition comprising a polypeptide molecule comprising an anti-T cell receptor beta variable region (TCRβV) binding domain,
wherein the anti-TCRβV binding domain comprises:
(i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) sequence, a HC CDR2 sequence, and a HC CDR3 sequence of any one of SEQ ID NOs: 142, 155, 170, 185, and 197, wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT); and
(ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1) sequence, a LC CDR2 sequence, and a LC CDR3 sequence of any one of SEQ ID NOs: 141, 154, 169, 184, and 196, wherein the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT); and
wherein the anti-TCRβV binding domain contacts a TCRβV of the TCR expressed by the subset of T cells in the T cell population, thereby selectively expanding the subset of T cells that express the TCR comprising the TCRβV targeted by the anti-TCRβV binding domain in the T cell population.